The emergence of mucormycosis as an important opportunistic fungal infection: Five cases presenting to a tertiary referral center for mycology

International Journal of Dermatology

Volumn 46, Issue 4, 2007, Pages 380-384

  Ameen, Mahreen ^a,b   Arenas, Roberto ^a,b   Martinez luna, Eduwiges ^a,b   Reyes, Miguel ^a,b   Zacarias, Rogelio ^a,b  

^a HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CEFOTAXIME; CEFTRIAXONE; CLARITHROMYCIN; CLINDAMYCIN; DIDANOSINE; FLUCONAZOLE; IMIPENEM; INDINAVIR; ITRACONAZOLE; STAVUDINE;

ADULT; AGED; ARTICLE; BRAIN INFECTION; CANDIDA ALBICANS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEBRIDEMENT; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FEMALE; FUNGUS CULTURE; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MALE; MAXILLA RESECTION; MEXICO; MORTALITY; MUCOR; MUCORMYCOSIS; MYCOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PATIENT REFERRAL; RADIOGRAPHY; RELAPSE; RISK FACTOR; SKIN INFECTION; SURVIVAL RATE; TERTIARY HEALTH CARE;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; DERMATITIS, PERIORAL; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; DIAGNOSIS, DIFFERENTIAL; EDEMA; FEMALE; FEVER; HUMANS; MALE; MUCORMYCOSIS;

EID: 34247131870     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.03057.x     Document Type: Article

References (18)

1. Sugar AM. Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 4th edn., Vol. 2. New York: Churchill Livingstone, 1995: 2311-2321.
2. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human diseases. Clin Microbiol Rev 2000; 13: 236-301.
3. Adams RD, Hunter G, Di Tomasso J, et al. Mucormycosis: Emerging prominence of cutaneous infections. Clin Infect Dis 1994; 19: 67-76.
4. Kontoyiannis DP, Wessel VC, Bodey GP, et al. Zygomycosis in the 1990s in a tertiary-care cancer centre. Clin Infect Dis 2000; 30: 851-856.
5. Sanchez MR, Ponge-Wilson I, Moy JA, et al. Zygomycosis and HIV infection. J Am Acad Dermatol 1994; 30: 904-908.
6. Pérez-Uribe A, Molina de Soschin D, Arenas R, et al. Mucormicosis cutánea primaria en un paciente con virus de la inmunodeficiencia humana. Rev Iberoam Micol 2005; 22: 116-119.
7. Ruiz-Avila J, Arenas R, Vega-Memije ME, et al. Mucormicosis rinocerebral por Rhizopus sp. Dermatologia Rev Mex 1995; 39: 80-93.
8. Greenberg RN, Scot LJ, Vaughn HH, et al. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004; 17: 517-525.
9. Yohai RA, Bullock JD, Aziz AA, et al. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 1994; 39: 3-22.
10. Gartenberg G, Bottone EJ, Keusch GT, et al. Hospital acquired mucormycosis (Rhizopus rhizopodiformis) of skin and subcutaneous tissue: epidemiology, mycology and treatment. N Engl J Med 1978; 299: 1115-1118.
11. Nagy-Agren SE, Chu P, Smith GJ, et al. Zygomycosis (mucormycosis) and HIV infection: Report of three cases and review. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 441-449.
12. Tarrand JJ, Lichterfeld M, Warraich I, et al. Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol 2003; 119: 854-858.
13. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487-3496.
14. Tobon AM, Arango M, Fernandez D, et al. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: Recovery after posaconazole therapy. Clin Infect Dis 2003; 36: 1488-1491.
15. Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J 2004; 23: 769-773.
16. Barratt DM, Van Meter K, Asmar P, et al. Hyperbaric oxygen as an adjunct in zygomycosis: Randomized controlled trial in a murine model. Antimicrob Agents Chemother 2001; 45: 3601-3602.
17. Lithander J, Louon A, Worthing E, et al. Orbital entomophthoramycosis in an infant: Recovery following surgical debridement, combination anti-fungal therapy and use of hyperbaric oxygen. Br J Ophthalmol 2001; 85: 374-375.
18. Losee JE, Selber J, Vega S, et al. Primary cutaneous mucormycosis: Guide to surgical management. Ann Plast Surg 2002; 49: 385-390.